Form 4: Athira Pharma General Counsel Reports Routine Stock Transaction Following RSU Vesting

Athira Pharma's General Counsel, Mark Worthington, reported the acquisition of common stock through RSU vesting and a subsequent sale of shares to cover tax obligations.

Summary

• Mark Worthington, General Counsel and Chief Compliance Officer of Athira Pharma, Inc. (ATHA), reported transactions related to his equity holdings.
• On June 30, 2025, 36,666 Restricted Stock Units (RSUs) vested and converted into an equal number of common stock shares.
• Following this vesting, Worthington's direct beneficial ownership of common stock was 120,401 shares.
• On July 1, 2025, 8,526 shares of common stock were sold at a weighted-average price of $0.2935 per share.
• This sale was non-discretionary and conducted to cover tax withholding and remittance obligations associated with the RSU vesting, as per the issuer's mandatory "sell to cover" policies.
• The shares were sold in multiple transactions within a price range of $0.2854 to $0.3031.
• After the sale, Worthington's direct beneficial ownership of common stock was 111,875 shares.
• Worthington still holds 36,667 Restricted Stock Units, which are scheduled to vest on December 31, 2025.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (RSU vesting and tax-related sale) which is neutral in sentiment. It does not indicate positive or negative operational performance or strategic shifts.

Positives

• The vesting of Restricted Stock Units indicates continued retention and alignment of management interests with shareholder value, as these are performance or time-based incentives.

Negatives

• The sale of shares, while for tax purposes, reduces the direct equity holding of a key executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to an individual's equity transaction.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and does not provide broader industry context or trends.

Related Party Transactions

• The vesting of Restricted Stock Units and subsequent sale of shares for tax purposes are part of the standard equity compensation agreement between the reporting person (an executive) and the issuer.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by an executive for tax purposes is a routine event and is unlikely to have a significant direct impact on the share price or shareholder value. It represents a minor reduction in direct insider ownership.
• Employees: The RSU vesting demonstrates the company's ongoing equity compensation practices for its executives, which is a standard part of employee incentive programs.

Next Steps

• The remaining 36,667 Restricted Stock Units held by Mark Worthington are scheduled to vest on December 31, 2025.

Key Dates

Keywords

Athira Pharma, ATHA, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU vesting, stock sale, tax withholding, Mark Worthington, General Counsel, Chief Compliance Officer, equity compensation